Compare STRT & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRT | NGNE |
|---|---|---|
| Founded | 1908 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 331.1M | 327.8M |
| IPO Year | 1996 | 2014 |
| Metric | STRT | NGNE |
|---|---|---|
| Price | $90.72 | $19.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $40.14 |
| AVG Volume (30 Days) | 34.5K | ★ 92.0K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.53 | N/A |
| EPS | ★ 3.26 | N/A |
| Revenue | ★ $439,195,000.00 | $925,000.00 |
| Revenue This Year | $4.22 | N/A |
| Revenue Next Year | $2.04 | N/A |
| P/E Ratio | $27.89 | ★ N/A |
| Revenue Growth | ★ 5.24 | N/A |
| 52 Week Low | $31.71 | $6.88 |
| 52 Week High | $92.50 | $37.27 |
| Indicator | STRT | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 59.53 | 56.21 |
| Support Level | $62.09 | $19.19 |
| Resistance Level | $92.45 | $20.50 |
| Average True Range (ATR) | 4.48 | 1.16 |
| MACD | -0.08 | 0.35 |
| Stochastic Oscillator | 85.91 | 77.74 |
Strattec Security Corp designs develops, manufactures, and markets mechanical locks, electronically enhanced locks, and keys. It also produces ignition lock housings; and access control products, including latches, power sliding door systems, and door handles. Strattec ships products to customer locations in the United States, Canada, Mexico, Europe, South America, Korea, and China, and provides full-service aftermarket support. Strattec also supplies products for the heavy truck and recreational vehicle markets, as well as precision, die castings.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.